Market research
VVY.AS Vivoryon Therapeutics N.V
AS EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 33M
- P/E ratio
- Not available
- Analyst target
- 6.85
- Dividend yield
- Not available
- Beta
- 1.45
Profile
Company facts
- Exchange
- AS
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL00150002Q7
- Market cap
- 33M
- P/E ratio
- Not available
- Analyst target
- 6.85
- Dividend yield
- Not available
- Beta
- 1.45
About
About Vivoryon Therapeutics N.V
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VVY.AS discussion.
5 years, 5 months ago
Vivoryon Therapeutics N.V is currently in a long term uptrend where the price is trading 72.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Vivoryon Therapeutics N.V gets an overall score of 2/5.